Graduate School of Biostudies, Kyoto University, Kyoto, 606-8502, Japan.
Next Generation Science Institute, Morinaga Milk Industry Co., Ltd., Zama, Kanagawa, 252-8583, Japan.
Curr Opin Biotechnol. 2022 Feb;73:108-120. doi: 10.1016/j.copbio.2021.06.023. Epub 2021 Aug 7.
Bifidobacteria are widely used as a probiotic for their health-promoting effects. To promote their growth, bifidogenic prebiotics, including human milk oligosaccharides (HMOs), have been added to supplements and infant formula. However, the efficacy of both probiotic and prebiotic interventions is often debated, as clinical responses vary significantly by case. Here, we review clinical studies that aimed to proliferate human-residential Bifidobacterium (HRB) strains in the gut, and we highlight the difference between responders and non-responders to such interventions through an ecological, niche-based perspective and an examination of the prevalence of genes responsible for prebiotic assimilation in HRB genomes. We discuss the criteria necessary to better evaluate the efficacy of probiotic and prebiotic interventions and the recent therapeutic potential shown by synbiotics.
双歧杆菌因其对健康的促进作用而被广泛用作益生菌。为了促进其生长,包括人乳寡糖 (HMO) 在内的双歧杆菌促生元已被添加到补充剂和婴儿配方奶粉中。然而,益生菌和益生元干预的效果常常存在争议,因为临床反应因病例而异。在这里,我们回顾了旨在促进肠道中人类常驻双歧杆菌(HRB)菌株增殖的临床研究,并通过生态位的角度和对 HRB 基因组中负责预生物同化的基因的流行程度的检查,突出了对这些干预措施有反应和无反应的个体之间的差异。我们讨论了评估益生菌和益生元干预效果的必要标准,以及最近通过共生体显示出的治疗潜力。